Open AccessSofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure
Author(s) -
Jérôme Dumortier,
François Bailly,
GeorgesPhilippe Pageaux,
Anaïs ValletPichard,
Sylvie Radenne,
François Habersetzer,
MarieClaude Gagnieu,
JeanDidier Grangé,
Anne Minello,
Olivier Guillaud,
Nassim Kamar,
Laurent Alric,
Vincent Leroy
Publication year - 2016
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfw348
Subject(s) - medicine , sofosbuvir , daclatasvir , ribavirin , gastroenterology , kidney disease , simeprevir , discontinuation , hepatitis c , hepatitis c virus , renal function , pegylated interferon , hemodialysis , cirrhosis , liver disease , immunology , virus
Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). Over the last few years, second-generation direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and sofosbuvir (SOF) is the backbone of most modern treatment strategies. Since SOF is eliminated through the kidney, the aim of this multicentre retrospective study was to assess its antiviral efficacy and safety in HCV-infected patients with severe renal failure [including haemodialysis (HD) patients].
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom